Rohto Mentholatum Nepal Pvt. Ltd. (“RMN”) has taken a significant step forward in its growth journey with the successful groundbreaking ceremony for its upcoming manufacturing facility in Bardibas, Mahottari District of Madhes Province, Nepal held on 14th May 2026.
The ceremony was graced by the presence of the Managing Director, Ms. Tran Dang Bich Thao, along with key members of the RMN. The event symbolized the beginning of an exciting new chapter—one that strengthens the company’s manufacturing footprint in Nepal and reinforces its long-term vision for sustainable growth.
The new facility reflects Rohto’s continued commitment to local production, operational excellence, and responsible business practices, while also deepening its contribution to Nepal’s people and society. Once operational, the factory is expected to play a meaningful role in economic development by generating employment opportunities, empowering local communities, and improving supply chain efficiency.
Aligned with RMN’s vision, the project underscores a strong focus on delivering high-quality products while upholding the highest standards of safety, environmental stewardship, and community engagement.
RMN is a subsidiary of Rohto Pharmaceutical Co., Ltd., a global leader in skincare and healthcare products. Since its establishment in Nepal in 2019 AD, RMN has been producing wide range of skincare products under its various umbrella brands like Acnes, Sunplay, Selsun, Hada Labo, Oxy and so on focusing on improving everyday wellness and quality of life for consumers. Its parent company, Rohto Pharmaceutical Co., Ltd., is a Japan-based multinational company with more than 125 year’s strong legacy in pharmaceuticals, dermatology, and consumer healthcare, known globally for its innovation-driven approach, high-quality standards, and commitment to combining science with care to create trusted healthcare solutions.